The Press Room

The Barbara Ann Karmanos Cancer Institute has been named one of America’s 2025 Best Hospitals for Cancer Care, Mammogram Imaging, Minimally Invasive Surgery, and Patient Experience by the Women’s Choice Award ® , America’s trusted referral source for the best in health care. This is the 12 th consecutive year Karmanos has been recognized by the Women’s Choice Award® since the inception of the national list. “It is an honor to be awarded the Women’s Choice Award. This recognition reflects the except...

MedPage Today Dipesh Uprety, M.D., FACP , medical oncologist, member of the  Phase I Clinical Trials  and  Thoracic Oncology  Multidisciplinary Teams, and member of the  Molecular Therapeutics Research Program  at Karmanos, was the lead investigator on a study titled, “Racial and socioeconomic disparities in survival among patients with metastatic non-small cell lung cancer,” published in the Journal of the National Cancer Institute. Dr. Uprety explained to MedPage Today so...

WDET 101.9 FM The Surgeon General released the Alcohol and Cancer Risk advisory at the beginning of January and suggests the link needs to be included on alcohol bottles. Najeeb Al Hallak, M.D., MS , medical oncologist and co-leader of the  Gastrointestinal and Neuroendocrine Oncology Multidisciplinary Team  at Karmanos, joined WDET’s The Metro to discuss the proposed label. Dr. Al Hallak explained that alcohol causes around 100,000 cancer cases and 20,000 cancer deaths a year and how he think...

The Barbara Ann Karmanos Cancer Institute welcomes José Larios, M.D. , transplant hematologist. Dr. Larios is a member of the Bone Marrow and Stem Cell Transplant and Hematology Oncology Multidisciplinary Teams at Karmanos. He specializes in treating leukemia and lymphoma blood cancers, including Hodgkin and non-Hodgkin lymphomas. He began seeing patients at the Karmanos Cancer Center in Detroit in August 2024. "Karmanos Cancer Institute is an NCI (National Cancer Institute)-Designated Comprehensive Can...

Becker’s Hospital Review The Barbara Ann Karmanos Cancer Institute is the first in the world to prescribe the TheraBionic P1 device , an at-home treatment for adults with advanced liver cancer. The device was approved by the FDA in September 2023 for adult patients who have failed first- and second-line treatments. Read the article here . Click here to learn more about the TheraBonic P1 device.

Patient Power Currently, multiple myeloma (MM) is uncurable, so oncologists try to find treatment options that will control the disease. Abhinav Deol, M.D. , hematologist, medical oncologist, and member of the  Bone Marrow and Stem Cell Transplant ,  Hematology Oncology  and  Multiple Myeloma and Amyloidosis  Multidisciplinary Teams at Karmanos, explained the success rates for using CAR T cell therapy to treat MM or stem cell transplantation. Read the article here .

The Detroit News The TheraBionic P1 device is now available for patients who have advanced liver cancer and have failed first- and second-line therapies. Boris Pasche, M.D., Ph.D., FACP , president and CEO of the Barbara Ann Karmanos Cancer Institute, chair of the Department of Oncology at Wayne State University, and co-inventor of the TheraBionic P1 device, and Anthony Shields, M.D., Ph.D. , medical oncologist and member of the  Gastrointestinal and Neuroendocrine Oncology Multidisciplinary Team ,...

The Barbara Ann Karmanos Cancer Institute , the largest provider of cancer care and research in Michigan and part of McLaren Health Care, announced today that the new TheraBionic P1 device, an FDA-approved, at-home treatment , is now available to treat advanced liver cancer. Karmanos Cancer Center is the first institution worldwide to prescribe this treatment. The TheraBionic P1 device is a novel, handheld, portable device that produces low levels of 27.12 MHz radiofrequency electromagnetic fields, whic...

WDET A foundation will offer scholarships and internships to medical students for assistance in recruiting underrepresented and disadvantaged individuals into clinical trials. Hayley Thompson, Ph.D., associate center director of Community Outreach and Education at Karmanos Cancer Institute and faculty supervisor of Karmanos’ Office of Cancer Health Equity and Community Engagement , applauded this work and explained why it's important for patients of color to consider participating in clinical trials. Sh...

Patient Power Yusra Shao, M.D. , medical oncologist and member of the  Genitourinary Oncology Multidisciplinary Team  at Karmanos, explained how immune checkpoint inhibitors work when treating bladder cancer, and the response rate for this therapy. Read the article here .